ClinConnect ClinConnect Logo
Search / Trial NCT02579278

Circulating Tumour DNA (ctDNA) in Patients With Colorectal Cancer and the Relationship to Imaging Features of Extramural Venous Invasion

Launched by IMPERIAL COLLEGE LONDON · Oct 16, 2015

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Emvi Extramural Venous Invasion Mr Emvi Rectal Cancer Ct Dna Neoplasm Dna Mri

ClinConnect Summary

This clinical trial is studying a specific type of genetic material called circulating tumor DNA (ctDNA) in patients with colorectal cancer, specifically looking at how it relates to certain imaging features of extramural venous invasion (EMVI). The goal is to better understand how ctDNA can provide information about the cancer and its behavior. This study does not involve randomization or treatment; instead, it focuses on collecting blood samples from patients who have been diagnosed with colorectal adenocarcinoma but do not have cancer that has spread to other parts of the body.

To join the study, patients must be at least 16 years old, have a confirmed diagnosis of colorectal cancer, and be eligible for surgery aimed at curing the cancer. They should not have any signs of cancer spread on their scans and must have completed a specific imaging test in the six weeks before their surgery. Participants will have two blood samples taken: one before surgery and another either during or shortly after the surgery. After that, they will be followed up annually for up to three years. This trial is currently looking for participants, and anyone interested should speak with their healthcare provider for more information.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Have a biopsy-confirmed colorectal adenocarcinoma
  • 2. Is eligible for curative surgery
  • 3. Has no metastatic disease on CT scan
  • 4. Has completed pre-operative staging scan within six weeks prior to surgery
  • 5. Have provided written informed consent to participate in the study
  • 6. Be aged 16 years or over
  • Exclusion Criteria:
  • 1. Have metastatic disease (including resectable liver metastases)
  • 2. Have a synchronous second malignancy
  • 3. Are contraindicated for any imaging able to determine EMVI status

About Imperial College London

Imperial College London is a world-renowned research institution based in the United Kingdom, recognized for its commitment to advancing medical science and improving patient care through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, Imperial combines expertise across various fields, including medicine, engineering, and business, to drive breakthroughs in healthcare. The institution’s robust clinical trial programs are designed to evaluate new therapies and interventions, ensuring rigorous scientific standards and ethical practices while aiming to translate research findings into tangible benefits for patients and society.

Locations

Margate, Kent, United Kingdom

Sutton, Surrey, United Kingdom

Hammersmith, London, United Kingdom

Patients applied

0 patients applied

Trial Officials

Gina Brown, MD

Principal Investigator

Imperial College London

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials